A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)

A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple…

read more

A phase I trial of selinexor, ruxolitinib and methylprednisolone for patients with relapsed/refractory multiple myeloma

A phase I trial of selinexor, ruxolitinib and methylprednisolone for patients with relapsed/refractory multiple myeloma…

read more

IMBCR & Emory University’s Big Discovery!

Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response…

read more

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Results from the I-RUX Study Published in ASH2020

January 19, 2021 WEST HOLLYWOOD, CA, January 19, 2021 – ONCOtherapeutics and Dr. James Berenson…

read more

James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center

New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative…

read more

Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Ruxolitinib, Methylprednisolone and Lenalidomide

Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Ruxolitinib, Methylprednisolone and Lenalidomide: Using Changes in…

read more

A Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy

A Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are…

read more

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients Sponsor: Incyte Protocol…

read more

A Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide

A Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide Combination Maintenance Therapy…

read more